Vaxcyte Financials - Benzinga

Vaxcyte Inc

PCVXNASDAQ

Trade with Public

Trade with Public

$56.90

0.410.72%

À la clôture: Sep 23, 5:00 PM EST

$56.80

0.300.54%

Pré-ouverture: 8:01 AM EST

Aperçu Actualités Prévisions de résultats Événements Objectifs de coursDonnées financièresSentiment Actionnariat Comparer Options Rapport sur les stocks

Vaxcyte Financials

Vaxcyte (PCVX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Vaxcyte Q2 EPS $(1.97) Beats $(2.22) Estimate

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.97) per share which beat the analyst consensus estimate of $(2.22) by 11.26 percent. This is a 61.48 percent decrease over losses of $(1.22) per share from the same

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Vaxcyte Q1 EPS $(2.30) Misses $(1.82) Estimate

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(2.30) per share which missed the analyst consensus estimate of $(1.82) by 26.37 percent. This is a 121.15 percent decrease over losses of $(1.04) per share from the

Benzinga Newsdesk

PRO
Vaxcyte Q4 EPS $(1.80) Misses $(1.56) Estimate

Vaxcyte (NASDAQ:PCVX) reported quarterly losses of $(1.80) per share which missed the analyst consensus estimate of $(1.56) by 15.38 percent. This is a 76.47 percent decrease over losses of $(1.02) per share from the

Benzinga Newsdesk

Earnings Scheduled For February 24, 2026

Benzinga Insights

Earnings Outlook For Vaxcyte

Benzinga Insights

© 2026 Benzinga | All Rights Reserved